Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?

The American Journal of Cardiology
C PrattA L Waldo

Abstract

The Survival With ORal D-sotalol (SWORD) trial tested the hypothesis that the prophylactic administration of oral d-sotalol would reduce total mortality in patients surviving myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) of < or = 40%. Two index MI groups were included: recent (6 to 42 days) and remote (> 42 days) with clinical heart failure (n = 915 and 2,206, respectively). The trial was discontinued when the statistical boundary for harm was crossed (RR = 1.65; p = 0.006). All baseline variables known to be associated with mortality risk (e.g., LVEF, heart failure class, age) as well as variables related to torsades de pointes (e.g., time from beginning of therapy, QTc, gender, potassium, renal function, dose of d-sotalol) were assessed for interaction of each variable with treatment assignment, computing RR and 95% confidence interval (CI) from Cox regression models. The d-sotalol-associated mortality was greatest in the group with remote MI and LVEFs of 31% to 40% (RR = 7.9; 95% CI 2.4 to 26.2). Most variables known to be associated with torsades de pointes were not differentially predictive of d-sotalol-associated risk, except female gender (RR = 4.7; 95% CI 1.4 to 16.5). These findings sugge...Continue Reading

Citations

Oct 7, 2000·Clinical and Experimental Pharmacology & Physiology·H J Witchel, J C Hancox
Nov 23, 2000·Physical Review. E, Statistical Physics, Plasmas, Fluids, and Related Interdisciplinary Topics·H M HastingsA Garfinkel
Jan 16, 2002·Cardiology in Review·William G StevensonWilliam H Maisel
Jul 6, 2005·European Heart Journal·Nicoline JochmannVerena Stangl
Jul 8, 2008·British Journal of Pharmacology·M K PugsleyM J Curtis
Jun 16, 2009·Congestive Heart Failure·Amber L ChakiAlan B Miller
Apr 3, 2014·Physiological Reviews·Nicole SchmittSøren-Peter Olesen
Mar 23, 2017·European Heart Journal. Cardiovascular Pharmacotherapy·J TamargoS Agewall
Nov 4, 2000·Expert Opinion on Investigational Drugs·S A Doggrell, L Brown
Oct 6, 2005·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Yanfei RuanLin Wang
Dec 26, 2006·Expert Review of Cardiovascular Therapy·Henri Roukoz, Walid Saliba
Dec 20, 2007·Cardiology in Review·Lori A Blauwet, Rita F Redberg
Jun 24, 2009·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Suresh Krishnamoorthy, Gregory Y H Lip
Jun 17, 2008·British Journal of Pharmacology·D M Roden
Oct 21, 2010·Journal of Cardiovascular Electrophysiology·Pasquale SantangeliAndrea Natale
Jul 13, 2016·Circulation·Robert L PageUNKNOWN American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical
Feb 28, 2020·The Cochrane Database of Systematic Reviews·Meaghan LunneyPietro Ravani
Feb 5, 1999·Current Opinion in Cardiology·D Wolbrette, H Patel
Mar 25, 1999·Journal of Cardiovascular Electrophysiology·C M Pratt
Feb 14, 2002·Clinical Cardiology·Deborah WolbretteAlan Kadish
Mar 19, 2002·American Journal of Therapeutics·Robert R Fenichel
Aug 13, 2004·Current Cardiology Reports·Deborah L Wolbrette
Sep 3, 2003·Journal of Cardiovascular Electrophysiology·Craig M Pratt
Apr 12, 2005·Drugs·Kristin E Ellison, Gaurang Gandhi
Sep 17, 2009·Journal of Cardiovascular Pharmacology·Michael R Rosen, Michiel J Janse
Aug 2, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M D Drici, N Clément
Apr 3, 2003·Congestive Heart Failure·Kristin E EllisonWilliam H Maisel
Aug 2, 2003·Journal of Veterinary Internal Medicine·Melissa R FinleyLisa C Freeman
Jun 26, 2018·European Journal of Pharmacology·Dongze ZhangYu-Long Li
Aug 10, 2020·Critical Pathways in Cardiology·Mohammad H AbbasiE Kevin Heist

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.